The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al. · Circulation · 2013 · 1.3K citations · Full text

Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes

Hiddo J.L. Heerspink, Dick de Zeeuw, Li Wie et al. · Diabetes Obesity and Metabolism · 2013 · 801 citations · Full text

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

Dick de Zeeuw, Rajiv Agarwal, Michael Amdahl et al. · The Lancet · 2010 · 686 citations

Renal Function, Vital Study, Diabetes +4

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

Donald E. Kohan, Paola Fioretto, Weihua Tang et al. · Kidney International · 2013 · 633 citations · Full text

Obesity, Metabolic Syndrome, Hypertension +14

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

Anthony Barnett, Ambrish Mithal, Jenny Manassie et al. · The Lancet Diabetes & Endocrinology · 2014 · 567 citations

Diabetes Management, Insulin Management, Diabetes +8